Corcept Therapeutics stock falls after Q2 2026 earnings jump and analyst focus on risk-reward
Published on 09/20/2026 at 20:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Corcept Therapeutics stock (ISIN US2176391003) closed at USD 110.29 on Nasdaq on September 18, 2026, down 3.98% from the prior session despite a sharply improved earnings profile in recent quarters per data compiled by MarketBeat and other portals on September 18, 2026.
Q2 2026 results show double-digit growth
According to Yahoo Finance on September 18, 2026, Corcept Therapeutics reported Q2 fiscal 2026 revenue of USD 256.15 million and earnings of USD 42.14 million, implying a profit margin of 16.45% for the quarter.
The same overview shows that Q2 FY26 earnings per share came in at USD 0.40 versus an earlier estimate of USD 0.10, meaning EPS was USD 0.30 above consensus and pointing to a significant positive surprise in the latest reported quarter as of mid-2026.
Analyst view and upside versus current price
As Yahoo Finance reports on September 18, 2026, HC Wainwright & Co. reiterated its Buy rating on Corcept Therapeutics and maintained a price target of USD 165, leaving the target unchanged on that date.
With the stock closing at USD 110.29 on September 18, 2026, this HC Wainwright target implies upside of roughly 49.6% from the latest closing price, illustrating that at least part of the analyst community still sees considerable headroom for Corcept Therapeutics stock despite recent volatility.
Stock performance and valuation context
Per data from MarketBeat updated on September 19, 2026, Corcept Therapeutics stock was trading at USD 34.80 at the beginning of calendar 2026 and has since risen to USD 110.29, corresponding to an increase of 216.9% year to date.
The same MarketBeat overview indicates consensus analyst coverage of eight firms with a Moderate Buy average rating score of 2.50 on a 0-to-4 scale, reflecting a generally constructive but not unanimous stance toward the shares as of September 19, 2026.
Profitability and longer-term fundamentals
According to Yahoo Finance on September 18, 2026, Corcept Therapeutics generated trailing twelve-month revenue of USD 830.81 million and net income attributable to common shareholders of USD 54.27 million, giving investors a broader view of the company’s scale and profitability beyond a single quarter.
A separate quantitative snapshot from Danelfin as of September 19, 2026, also lists sales of roughly USD 830.81 million and income of about USD 54.2 million, with year-on-year sales growth of 31.74%, reinforcing the picture of double-digit top-line expansion in the latest reporting periods.
Upcoming earnings date and calendar
Per the company calendar summarized on MarketBeat as of September 19, 2026, the last earnings report took place on July 29, 2026, which aligns with Corcept Therapeutics’ Q2 FY26 disclosure.
The same calendar lists an estimated next earnings date of November 4, 2026, for Corcept Therapeutics, giving investors a provisional timeline for the next set of quarterly figures, although this date remains an estimate rather than a formally confirmed investor-relations announcement.
Stock level and market capitalization
At the Nasdaq closing price of USD 110.29 on September 18, 2026, Corcept Therapeutics stock stands well above its level at the start of 2026 and below the reiterated HC Wainwright price target, reflecting both strong execution in recent quarters and ongoing debate about valuation and future growth.
Key facts on Corcept Therapeutics stock
- Company: Corcept Therapeutics Incorporated
- ISIN: US2176391003
- Ticker: CORT
- Trading venue: Nasdaq
- Price (as of September 18, 2026, 16:00): 110.29 USD
- Market capitalization: 830.81 million USD (as of September 18, 2026, based on trailing revenue proxy)
- Sector / Industry: Health Care / Biotechnology
- Index membership: Nasdaq Composite
- Next earnings date: November 4, 2026 (estimated)
